Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
基本信息
- 批准号:10263928
- 负责人:
- 金额:$ 18.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsApplications GrantsBasal cell carcinomaBindingBiological AvailabilityBreedingChemopreventionChemopreventive AgentChronicClinical TrialsCyclosporineDataDevelopmentDoseDrug KineticsEvaluationExposure toGenotypeGoalsHistologicHumanIACUCImmunocompetentImmunosuppressionIn VitroInbred HRS MiceLeadLipidsMalignant Epithelial CellMorbidity - disease rateMusOralOrganOrgan TransplantationPlayPredispositionPreventionProgram Research Project GrantsProtocols documentationRXRResearch PersonnelRoleSafetyScientistSerumServicesSkinSkin CancerSkin CarcinomaSkin NeoplasmsSquamous cell carcinomaStainsTestingTissuesToxic effectToxicologyTransplant RecipientsTriglyceridesUVB inducedUltraviolet Raysanimal breedinganimal dataanimal tissuebasecancer chemopreventionclinical applicationdesignexperimental studyimmunosuppressedin vivomortalitymouse modelnovelpre-clinicalpreclinical efficacypremalignantprogramsreceptorresponsescreeningskin cancer preventionskin lesiontooltumorigenesisultraviolet irradiation
项目摘要
The Rexinoid Screening and Animal Core (Animal Core) is a critical component of the Program
Project Grant. It supports the goals and objectives of the Program by providing pre-clinical
efficacy and safety information on novel rexinoids, designed by Project 2, that have the potential
to be useful as chemopreventive agents for non-melanoma skin cancers in organ transplant
recipients. Effective dose 50 (ED50) for prevention of non-melanoma skin cancer in normal and
cyclosporine-treated mice will be established for each candidate rexinoid; the ED50 of our
current lead compound, UAB30, which will be used as a comparator. Pharmacokinetics,
tolerability, organ toxicity and lipid abnormalities of the newly synthesized rexinoids will also be
determined. Another service provided by the Rexinoid Screening and Animal Core is to
maintain a colony of Ptch+/-/SKH1 mice. Following chronic exposure to UV radiation, these mice
develop basal cell carcinomas, squamous cell carcinomas and premalignant actinic keratoses.
Thus, they carefully replicate human skin cancer susceptibility to UV. Maintaining a breeding
colony of these unique mice will be particularly important for the experiments proposed in
Projects 2 and Project 3. Tissues from these mice will also be banked and made available for
analysis to Program investigators. Core scientists will also provide assistance in development
of experimental protocols, IACUC approvals, and help with UV irradiation and
immunosuppression protocols.
Rexinoid筛查和动物核心(动物核心)是该程序的关键组成部分
项目赠款。它通过提供临床前来支持计划的目标和目标
由项目2设计的有关新型雷克尼素的功效和安全信息,具有潜力
可用作器官移植中非黑色甲烷瘤皮肤癌的化学预防剂
收件人。有效剂量50(ED50)预防正常和
将为每种候选雷克诺类似的环孢菌素治疗的小鼠建立;我们的ED50
当前的铅化合物UAB30将用作比较器。药代动力学,
新合成的rexinoids的耐受性,器官毒性和脂质异常也将是
决定。 Rexinoid筛选和动物核心提供的另一项服务是
保持PTCH+/ - /SKH1小鼠的菌落。长期暴露于紫外线辐射后,这些小鼠
发展基底细胞癌,鳞状细胞癌和举止举世主的角化作用。
因此,他们仔细地复制了人类皮肤癌对紫外线的敏感性。保持繁殖
这些独特小鼠的菌落对于提出的实验尤其重要
项目2和项目3。这些小鼠的组织也将被库存并提供
分析计划调查人员。核心科学家还将为开发提供帮助
实验方案,IACUC批准以及帮助紫外线照射和
免疫抑制方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Athar其他文献
Mohammad Athar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Athar', 18)}}的其他基金
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10700044 - 财政年份:2020
- 资助金额:
$ 18.62万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10023318 - 财政年份:2020
- 资助金额:
$ 18.62万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10259711 - 财政年份:2020
- 资助金额:
$ 18.62万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10886403 - 财政年份:2020
- 资助金额:
$ 18.62万 - 项目类别:
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)
核心 4:动物育种 (UAB) 和暴露核心 (MRIGLOBAL)
- 批准号:
10249112 - 财政年份:2018
- 资助金额:
$ 18.62万 - 项目类别:
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury
项目1:化学糜烂介导的皮肤损伤的新型药理抑制剂
- 批准号:
10249113 - 财政年份:2018
- 资助金额:
$ 18.62万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
9767149 - 财政年份:2018
- 资助金额:
$ 18.62万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
10249107 - 财政年份:2018
- 资助金额:
$ 18.62万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10493962 - 财政年份:2017
- 资助金额:
$ 18.62万 - 项目类别:
相似海外基金
Basal Cell Polarity Proteins in Normal Tissue Homeostasis and Cancer
正常组织稳态和癌症中的基底细胞极性蛋白
- 批准号:
10667590 - 财政年份:2019
- 资助金额:
$ 18.62万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10007604 - 财政年份:2017
- 资助金额:
$ 18.62万 - 项目类别:
Regulation of Quiescence and Activation in Skin Stem Cells
皮肤干细胞静止和激活的调节
- 批准号:
8902307 - 财政年份:2014
- 资助金额:
$ 18.62万 - 项目类别:
Regulation of Quiescence and Activation in Skin Stem Cells
皮肤干细胞静止和激活的调节
- 批准号:
8920475 - 财政年份:2014
- 资助金额:
$ 18.62万 - 项目类别:
Regulation of Quiescence and Activation in Skin Stem Cells
皮肤干细胞静止和激活的调节
- 批准号:
8509979 - 财政年份:2013
- 资助金额:
$ 18.62万 - 项目类别: